Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study.
Bone marrow
DTC
Disseminated tumor cells
PDAC
Pancreatic ductal adenocarcinoma
Prognosis
Survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
03 Jun 2022
03 Jun 2022
Historique:
received:
14
01
2022
accepted:
24
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Although pancreatic ductal adenocarcinoma (PDAC) rarely metastasizes to the skeleton, disseminated tumor cells have been detected in bone marrow samples from patients with this disease. The prognostic value of such findings is currently unclear. Thus, the current study aimed to clarify the prognostic information associated with disseminated tumor cell detection in samples from patients with PDAC. Bone marrow aspirates were obtained from 48 patients with locally advanced (n = 11) or metastatic (n = 37) PDAC, before and after 2 months of chemotherapy. Disseminated tumor cells were detected with an mRNA panel and quantitative reverse transcription PCR. We used the highest levels measured in healthy bone marrow (n = 30) as a threshold to define the positive detection of disseminated tumor cells. Progression-free and overall survival were analyzed with Kaplan-Meier and Cox proportional hazards regression analyses. Disseminated tumor cells were detected in 15/48 (31%) bone marrow samples obtained before starting chemotherapy and in 8/25 (32%) samples obtained during chemotherapy. Patients with disseminated tumor cells detected before therapy had significantly shorter progression-free (p = 0.03; HR = 2.0) and overall survival (p = 0.03; HR = 2.0), compared to those without disseminated tumor cells in the bone marrow. When restricting disseminated tumor cell detection to keratins KRT7 and KRT8, the prognostic information was substantially stronger (p = 1 × 10 Disseminated tumor cells detected before commencing chemotherapy had prognostic value in patients with inoperable PDAC.
Sections du résumé
BACKGROUND
BACKGROUND
Although pancreatic ductal adenocarcinoma (PDAC) rarely metastasizes to the skeleton, disseminated tumor cells have been detected in bone marrow samples from patients with this disease. The prognostic value of such findings is currently unclear. Thus, the current study aimed to clarify the prognostic information associated with disseminated tumor cell detection in samples from patients with PDAC.
METHODS
METHODS
Bone marrow aspirates were obtained from 48 patients with locally advanced (n = 11) or metastatic (n = 37) PDAC, before and after 2 months of chemotherapy. Disseminated tumor cells were detected with an mRNA panel and quantitative reverse transcription PCR. We used the highest levels measured in healthy bone marrow (n = 30) as a threshold to define the positive detection of disseminated tumor cells. Progression-free and overall survival were analyzed with Kaplan-Meier and Cox proportional hazards regression analyses.
RESULTS
RESULTS
Disseminated tumor cells were detected in 15/48 (31%) bone marrow samples obtained before starting chemotherapy and in 8/25 (32%) samples obtained during chemotherapy. Patients with disseminated tumor cells detected before therapy had significantly shorter progression-free (p = 0.03; HR = 2.0) and overall survival (p = 0.03; HR = 2.0), compared to those without disseminated tumor cells in the bone marrow. When restricting disseminated tumor cell detection to keratins KRT7 and KRT8, the prognostic information was substantially stronger (p = 1 × 10
CONCLUSIONS
CONCLUSIONS
Disseminated tumor cells detected before commencing chemotherapy had prognostic value in patients with inoperable PDAC.
Identifiants
pubmed: 35659265
doi: 10.1186/s12885-022-09714-x
pii: 10.1186/s12885-022-09714-x
pmc: PMC9166481
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
609Subventions
Organisme : Kreftforeningen
ID : 212734-2019
Organisme : Helse Vest
ID : 912009
Organisme : Helse Vest
ID : 990222
Organisme : Helse Vest
ID : 990222
Organisme : Folke Hermansen Foundation
ID : 422109
Informations de copyright
© 2022. The Author(s).
Références
J Cancer Res Clin Oncol. 2005 Oct;131(10):669-76
pubmed: 16136352
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Science. 2019 Dec 20;366(6472):
pubmed: 31857451
BMC Cancer. 2012 Dec 22;12:616
pubmed: 23259667
Br J Cancer. 2006 Mar 13;94(5):672-80
pubmed: 16495933
Biochemistry. 2004 Feb 10;43(5):1283-95
pubmed: 14756564
Clin Breast Cancer. 2010 Oct 1;10(5):378-84
pubmed: 20920982
Ann Surg Oncol. 2018 Dec;25(13):4027-4034
pubmed: 30298331
Oncotarget. 2017 Aug 04;8(63):107223-107236
pubmed: 29291024
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Eur J Cancer. 1996 Feb;32A(2):363-5
pubmed: 8664055
World J Surg. 1999 Sep;23(9):888-91
pubmed: 10449815
Eur J Cancer. 2019 Jan;106:99-105
pubmed: 30476732
BMC Cancer. 2020 Nov 16;20(1):1107
pubmed: 33198661
Cancer Res. 1997 Aug 1;57(15):3106-10
pubmed: 9242433
Front Med. 2018 Aug;12(4):361-373
pubmed: 30043221
Breast Cancer Res Treat. 2008 Mar;108(2):251-8
pubmed: 17492378
Semin Cancer Biol. 2020 Feb;60:138-147
pubmed: 31376430
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 2005 Dec 20;23(36):9067-72
pubmed: 16172462
Cell. 2009 Dec 24;139(7):1315-26
pubmed: 20064377
World J Gastroenterol. 2007 Jan 14;13(2):257-63
pubmed: 17226905
Clin Cancer Res. 2007 Sep 1;13(17):5001-9
pubmed: 17785550
Int J Cancer. 2012 Aug 15;131(4):E475-83
pubmed: 21932421
Adv Cancer Res. 2019;141:43-84
pubmed: 30691685
Gynecol Oncol. 2007 Nov;107(2):331-8
pubmed: 17764727
Breast Cancer Res. 2016 Feb 12;18(1):20
pubmed: 26868521
Breast Cancer Res Treat. 2011 Feb;125(3):729-38
pubmed: 20449649
Pancreatology. 2021 Apr;21(3):556-563
pubmed: 33518454
Adv Exp Med Biol. 2020;1220:35-43
pubmed: 32304078
Surgery. 2001 May;129(5):537-46
pubmed: 11331445